CO6481008A2 - Canfenos arilados novedosos, procesos para su preparación y usos - Google Patents

Canfenos arilados novedosos, procesos para su preparación y usos

Info

Publication number
CO6481008A2
CO6481008A2 CO12084123A CO12084123A CO6481008A2 CO 6481008 A2 CO6481008 A2 CO 6481008A2 CO 12084123 A CO12084123 A CO 12084123A CO 12084123 A CO12084123 A CO 12084123A CO 6481008 A2 CO6481008 A2 CO 6481008A2
Authority
CO
Colombia
Prior art keywords
processes
preparation
canfenes
ariled
new
Prior art date
Application number
CO12084123A
Other languages
English (en)
Inventor
Raphael Mechoulam
Lital Magid
Itai Bab
Esther Shohami
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43875675&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6481008(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of CO6481008A2 publication Critical patent/CO6481008A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

La presente invención se refiere a canfenos arilados, los procesos para su preparación y sus usos a los fines de la fabricación de medicamentos para el tratamiento de enfermedades, trastornos o afecciones que se relacionan con la estimulación de los receptores CB2 o que se benefician de ella.
CO12084123A 2009-11-19 2012-05-22 Canfenos arilados novedosos, procesos para su preparación y usos CO6481008A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26267709P 2009-11-19 2009-11-19

Publications (1)

Publication Number Publication Date
CO6481008A2 true CO6481008A2 (es) 2012-07-16

Family

ID=43875675

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12084123A CO6481008A2 (es) 2009-11-19 2012-05-22 Canfenos arilados novedosos, procesos para su preparación y usos

Country Status (24)

Country Link
US (2) US8722938B2 (es)
EP (1) EP2501669B1 (es)
JP (1) JP5960058B2 (es)
KR (1) KR20120091196A (es)
CN (1) CN102648174B (es)
AU (1) AU2010320467B2 (es)
BR (1) BR112012010518A2 (es)
CA (1) CA2774868C (es)
CL (1) CL2012001290A1 (es)
CO (1) CO6481008A2 (es)
CR (1) CR20120247A (es)
EC (1) ECSP12011864A (es)
ES (1) ES2665519T3 (es)
IL (1) IL218216A (es)
MA (1) MA33753B1 (es)
MX (2) MX355972B (es)
MY (1) MY184647A (es)
NZ (1) NZ599106A (es)
PE (1) PE20121187A1 (es)
RU (1) RU2578715C2 (es)
SG (2) SG10201407706VA (es)
UA (1) UA109414C2 (es)
WO (1) WO2011061744A2 (es)
ZA (1) ZA201200752B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2578715C2 (ru) * 2009-11-19 2016-03-27 Йиссум Рисерч Дивелопмент Компани Оф Дзе Хебрю Юниверсити Оф Иерусалим, Лтд. Новые арилированные камфены, способы их получения и их применения
CN106795121A (zh) 2014-10-27 2017-05-31 豪夫迈·罗氏有限公司 放射性标记***素受体2配体
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
RU2701565C1 (ru) * 2015-10-16 2019-09-30 Импакт Биосайенсес Корп. Способы и композиции для лечения черепно-мозговой травмы
EP3538507A1 (en) 2016-11-13 2019-09-18 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Process for the preparation of hu-910 and crystalline structure thereof
RU2651754C1 (ru) * 2016-11-25 2018-04-23 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) ПРИМЕНЕНИЕ АЛИФАТИЧЕСКИХ ИМИНОПРОИЗВОДНЫХ КАМФОРЫ В КАЧЕСТВЕ ЭФФЕКТИВНЫХ ИНГИБИТОРОВ РЕПРОДУКЦИИ ВИРУСА ГРИППА штамм A/California/07/09 (H1N1) pdm09 и A/Puerto Rico/8/34 (H1N1)
KR102063962B1 (ko) * 2017-10-25 2020-01-08 대구대학교 산학협력단 캄펜을 유효성분으로 함유하는 골다공증의 예방 또는 치료용 약학적 조성물
KR20210090609A (ko) * 2018-08-20 2021-07-20 베서, 파마 엘엘씨 공지된 신규 칸나비노이드의 응용
WO2023058033A1 (en) * 2021-10-10 2023-04-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Arylated fenchone derivatives, compositions comprising them, processes for their preparation and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE876241C (de) * 1943-04-07 1953-05-11 Lech Chemie Gersthofen Verfahren zur Herstellung von Riechstoffen aus Terpenphenolen
US2537647A (en) * 1948-02-21 1951-01-09 Firestone Tire & Rubber Co Rearrangement of terpenyl aryl ethers
DE828394C (de) * 1948-10-02 1952-01-17 Chemische Werke Huels G M B H Verfahren zur Herstellung von UEberzuegen
US2647152A (en) * 1950-07-12 1953-07-28 Firestone Tire & Rubber Co Terpenylalkylphenols and their preparation
US3284359A (en) * 1963-12-26 1966-11-08 Gen Electric Barium potassium ferrite magnetic material exhibiting non-vanishing rotational hysteresis in applied magnetic fields
GB1306217A (es) * 1969-07-04 1973-02-07
US3800051A (en) * 1970-09-21 1974-03-26 Dow Chemical Co Reducing serum cholesterol with certain substituted phenols
GB1504862A (en) 1974-04-11 1978-03-22 Mar Pha Etu Expl Marques Terpeno-phenoxyalkylamines
US4112000A (en) * 1974-04-11 1978-09-05 Mar-Pha, Societe D'etude Et D'exploitation De Marques Terpenophenols
GB1548875A (en) * 1975-06-23 1979-07-18 Mar Pha Etu Expl Marques Terpnyl phen (oxy)elkyl amideines and their use in pharmaceutical compositions
US5648352A (en) 1991-09-13 1997-07-15 Merck & Co., Inc. Piperazinylcamphorsulfonyl oxytocin antagonists
HU227114B1 (en) 1999-05-11 2010-07-28 Egis Gyogyszergyar Nyilvanosan (1r, 2s, 4r)-(-)-2-[n,n-(dimethylamino-ethoxy)]-2-phenyl-1,7,7-trimethyl-bicyclo[2.2.1]heptane of high purity and pharmaceutically acceptable acid addition salts thereof, process for preparation of them and medicaments containing the same
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
PL362930A1 (en) * 2000-11-08 2004-11-02 Syngenta Participations Ag Pyrrolcarboxamides and pyrrolcarbothioamides and their agrochemical uses
US8455687B2 (en) 2002-05-31 2013-06-04 Proteotech, Inc. Compounds and compositions for use as modulators of tau aggregation and alleviation of tauopathies
SI2527315T1 (sl) * 2002-05-31 2014-06-30 Proteotech Inc., Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
US20070276034A1 (en) * 2002-05-31 2007-11-29 Luke Esposito Compounds, compositions and methods for the treatment of synucleinopathies
US8227643B2 (en) 2002-05-31 2012-07-24 Proteotech, Inc. Sirtuin 1 and the treatment of neurodegenerative diseases
US7601876B2 (en) 2002-05-31 2009-10-13 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis
RU2233262C1 (ru) * 2003-03-11 2004-07-27 Государственное учреждение Институт химии Коми научного центра Уральского отделения РАН Способ получения орто-терпенофенолов
CN1847207A (zh) * 2006-03-27 2006-10-18 上海应用技术学院 合成檀香的制备方法
RU2578715C2 (ru) * 2009-11-19 2016-03-27 Йиссум Рисерч Дивелопмент Компани Оф Дзе Хебрю Юниверсити Оф Иерусалим, Лтд. Новые арилированные камфены, способы их получения и их применения

Also Published As

Publication number Publication date
KR20120091196A (ko) 2012-08-17
US20150038728A1 (en) 2015-02-05
ZA201200752B (en) 2014-06-25
CL2012001290A1 (es) 2012-10-05
ECSP12011864A (es) 2012-07-31
CR20120247A (es) 2012-06-12
CA2774868C (en) 2018-09-04
AU2010320467A1 (en) 2012-04-05
CN102648174A (zh) 2012-08-22
CN102648174B (zh) 2016-04-27
RU2012106897A (ru) 2013-12-27
ES2665519T3 (es) 2018-04-26
SG10201407706VA (en) 2015-02-27
JP5960058B2 (ja) 2016-08-02
US9365534B2 (en) 2016-06-14
EP2501669A2 (en) 2012-09-26
BR112012010518A2 (pt) 2016-03-15
WO2011061744A3 (en) 2011-09-29
US20120245366A1 (en) 2012-09-27
MY184647A (en) 2021-04-13
UA109414C2 (uk) 2015-08-25
MX2012005634A (es) 2012-09-07
EP2501669B1 (en) 2018-01-24
IL218216A0 (en) 2012-04-30
RU2578715C2 (ru) 2016-03-27
PE20121187A1 (es) 2012-09-23
MX355972B (es) 2018-05-07
MA33753B1 (fr) 2012-11-01
US8722938B2 (en) 2014-05-13
WO2011061744A2 (en) 2011-05-26
SG179203A1 (en) 2012-04-27
IL218216A (en) 2015-05-31
JP2013511511A (ja) 2013-04-04
NZ599106A (en) 2013-07-26
AU2010320467B2 (en) 2015-07-02
CA2774868A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
CO6481008A2 (es) Canfenos arilados novedosos, procesos para su preparación y usos
ECSP17064695A (es) Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
DOP2017000013A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CL2014003388A1 (es) Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
UY33735A (es) Compuestos antivirales
UY32629A (es) Compuestos antivirales, composiciones y uso para la manufactura de un medicamento para el tratamiento de trastornos asociados con hepatitis c.
BR112015021495A2 (pt) fabricação contínua integrada de substâncias de droga de proteína terapêutica
UY36126A (es) ?compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr?.
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
GT201400089A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
CO6400193A2 (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
GT201300324A (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
CR20140431A (es) Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
CR11818A (es) Derivados de triazol utiles para el tratamiento de enfermedades
GT200500291A (es) Nuevos heterociclos
CO6491096A2 (es) Derivados de cromona, procesos para su preparación y aplicaciones terapeúticas de los mismos
CR20140553A (es) Compuestos de fenoxietil piperidina
UY31243A1 (es) Compuestos de 2-aza-biciclo[2.2.2]octano y usos para los mismos
UY31322A1 (es) Amidas heterocíclicas y sus métodos de uso-975
GT201400242A (es) "nuevos compuestos de pirazol"
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?

Legal Events

Date Code Title Description
FG Application granted